Clinical trial · Observational
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
Analysis of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Receiving Pomalidomide-Containing and Non-Pomalidomide-Containing Regimens in the Real World: A OneOncology United States Database Study
NCT07689006CI-TRIAL-00117145completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after prior exposure to lenalidomide and a proteasome inhibitor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-pomalidomide-containing regimens | Drug | — | UNRESOLVED |
| Pomalidomide-containing regimens | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Pomalidomide-containing regimens
- description
- Participants who initiated daratumumab, pomalidomide, and dexamethasone (DPd) or carfilzomib, pomalidomide, and dexamethasone (KPd) index regimens in the 2L or 3L setting after prior exposure to lenalidomide and a proteasome inhibitor.
- interventionNames
- Drug: Pomalidomide-containing regimens
- label
- Non-pomalidomide-containing regimens
- description
- Participants who initiated daratumumab, lenalidomide, and dexamethasone (DRd), or daratumumab, bortezomib, and dexamethasone (DVd), or daratumumab, carfilzomib, and dexamethasone (DKd) index regimens in the 2L or 3L setting after prior exposure to lenalidomide and a proteasome inhibitor.
- interventionNames
- Drug: Non-pomalidomide-containing regimens
Primary outcomes (4)
- measure
- Progression-Free Survival (PFS) among participants who initiated pomalidomide-containing index regimens
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have a diagnosis of multiple myeloma (ICD-9: 203.00; ICD-10: C90.0x, C90) * Are ≥18 years of age at the index date * Have received a lenalidomide-containing regimen and received a proteasome inhibitor; exposures do not need to occur within the same line of therapy * Have received ≥1 subsequent lines of therapy after lenalidomide and proteasome inhibitor exposure * Have received one of the following treatment regimens as the subsequent line (index line) after lenalidomide and proteasome inhibitor exposure: * Pomalidomide-containing regimens: * Daratumumab, pomalidomide, and dexamethasone (DPd) * Carfilzomib, pomalidomide, and dexamethasone (KPd) * Non-pomalidomide-containing regimens: * Daratumumab, lenalidomide, and dexamethasone (DRd; lenalidomide-refractory participants only) * Daratumumab, bortezomib, and dexamethasone (DVd) * Daratumumab, carfilzomib, and dexamethasone (DKd) Exclusion Criteria: * Have \<6 months of follow-up from the index date; participants who died will be included even with \<6 months follow-up, but participants who died within 1 month after the index date will be excluded * Have \<6 months pre-index enrollment * Have other primary cancer diagnoses within 1 year pre-index * Excluded ICD-10 diagnosis codes: C00.xx-C76.xx, C7A, C80.xx-C88.xx, C91.xx-C96.xx, D00.xx-D09.xx, D37.xx-D47.1x, D47.3x-D49.xx * Excluded ICD-9 diagnosis codes: 149.x through 239.x * ICD codes 209.4, 209.5, 209.6, 209.7, D47.Z1, D47.Z2, and D3A will not be excluded * Received chimeric antigen receptor T-cell therapy or bispecific antibody therapy before index date or as the index line * Have ever enrolled in a clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.